GlassScriptPhysician profile
Eric D Christoff
NPI 1245287317
$37,891.43
in general payments reported to CMS, 2019-2025
37 companies · $3,757 in 2025
The $3,757 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,266 · 2021: $9,359 · 2022: $2,871 · 2023: $3,711 · 2024: $3,419 · 2025: $3,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,886.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $17,412.04 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $13,290.78 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $1,462.46 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $995.84 | 2020-2025 | Vraylar |
| Theratechnologies INC. | $987.36 | 2023-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Napo Pharmaceuticals INC | $698.16 | 2019-2025 | Mytesi |
| Janssen Biotech, INC. | $631.34 | 2019-2023 | Symtuza |
| Janssen Products, LP | $299.94 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $259.28 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $256.84 | 2019-2025 | Wegovy |
| Pfizer INC. | $233.29 | 2023-2025 | |
| Amgen INC. | $219.44 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $206.96 | 2022-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.76 | 2022-2025 | Caplyta |
| Dynavax Technologies Corporation | $121.97 | 2021-2024 | Heplisav-B |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Christoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.